Jtekt India Q1 FY27: PAT falls 42% YoY, margins compress despite 27% revenue growth
PAT -42.48% YoY · revenue +26.85% · margins compressing
₹717.98 Cr
+26.85% YoY
₹6.22 Cr
-42.48% YoY
0.86%
-1pp YoY
₹0.22
Jtekt India's standalone Q1 FY27 (quarter ended 30 June 2026) results show a sharp profitability squeeze even as the topline grew: revenue from operations rose 26.9% YoY to ₹717.98 Cr (from ₹566.02 Cr in Q1 FY26), but net profit fell 42.5% YoY to ₹6.22 Cr (from ₹10.82 Cr), with EPS down to ₹0.22 from ₹0.42. Sequentially the decline is sharper still — PAT is down 77.4% QoQ from ₹27.49 Cr, even though revenue slipped a more modest 8.0% QoQ from ₹780.33 Cr, underlining this is a margin story rather than a demand story. No exceptional items hit either the current or year-ago quarter, so the decline is entirely operational rather than a one-off distortion.
Q1 FY-2027 vs prior quarters
The margin bridge points to costs running ahead of revenue: net profit margin compressed to ~0.87% of total income from 1.88% YoY and 3.51% QoQ, while EBIT margin (profit before exceptional items and tax, over revenue) fell to 1.20% from 2.57% YoY and 5.24% QoQ. Employee benefit expense rose 21.0% YoY and 18.3% QoQ to ₹80.93 Cr — the single largest swing factor, moving opposite to the revenue trend in both comparisons. Materials cost also crept up to 72.8% of revenue versus 71.0-72.0% in the comparison quarters, a modest mix drag. Depreciation (+34.9% YoY to ₹28.31 Cr) and finance costs (+23.8% YoY to ₹5.20 Cr) both rose faster than revenue, consistent with new production lines the company has been commissioning using rights-issue proceeds.
The stock went into the print at ₹133.16, down 6.2% over the past month of trading.
What the summary numbers don't show
No exceptional items this quarter (vs ₹2.45 Cr exceptional gratuity charge in Q4 FY26); results are unaudited, reviewed by B S R & Co. LLP.
Management is optimistic about continued revenue growth, expecting to add approximately INR 800 crores in the next year through a combination of market growth and increased export business. They anticipate full capacity utilization for newly commissioned lines within the next 1 to 1.5 years, leading to improved ROCE. W
— This quarter: missed
Against management's own May 2026 guidance — continued revenue growth toward ~₹800 Cr of annual additions, full utilisation of new lines within 1-1.5 years improving ROCE, and near-term margin pressure from product mix/accounting issues expected to normalise — this quarter is mixed: revenue growth of 26.9% YoY is broadly on the pace management flagged, but the margin pressure has not normalised — it has worsened both YoY and QoQ, so the quarter reads as a miss on the margin leg of that guidance. No specific street consensus estimates for this quarter were found (a Univest preview flagged raw-material cost volatility as a key margin risk without giving a PAT figure), so vs-street is unknown. The 2 July exchange clarification on 'volume surge, market driven factors' aligns with the strong YoY revenue print but does not explain the cost side. Separately, the board has set 7 August as record date and 26 August as AGM date for the ₹0.75/share FY26 final dividend already approved in May; the company also received a ₹622.39 demand notice for MEIS scrips on 4 August, a tax matter not reflected as an exceptional item in this statement. No standalone management press release beyond the exchange filing was available to cross-check management's own framing of the quarter.
W1
Employee cost ratio (11.3% of revenue this quarter) — watch for reversion toward the 8.8-11.8% range seen in the comparison quarters as new lines ramp up.
W2
Materials cost ratio (72.8% of revenue) — management guided margin improvement from higher-value CVJ/export mix; watch for reversion toward Q4 FY26's 71.0%.
W3
Progress toward full utilisation of newly commissioned lines (guided 1-1.5 years from May 2026) and the associated ROCE improvement management flagged.
Margin Recovery Under Scrutiny as Valuation Premium Persists
Upgraded to Buy but trading at 47.7x trailing P/E, JTEKT India must prove CVJ driveline momentum and gross margin recovery in Q1. Street targets ₹192, but EPS expected to decline 13% in FY27E—execution on new products and mix is critical.
The Setup
JTEKT India was upgraded to Buy on August 5, 2026, with a ₹192 target (36% upside from current levels). The bull case rests on three pillars: (1) gross margin recovery as input costs soften, (2) the CVJ (Constant Velocity Joint) driveline ramping at 45% CAGR from a small base (4% of revenue), and (3) EV portfolio and export expansion driving mix improvement. However, at 47.7x trailing P/E and a PEG of 24.9, the stock is priced for near-flawless execution. Street consensus for FY27E is 5–6% revenue growth but a 13% decline in EPS—a critical divergence that puts the valuation thesis on trial.
~5–6% YoY
Analyst consensus expects 5.3% FY27E; festive demand recovery and softer input costs are tailwinds
~9–10%
Systematix projects 240bps expansion over FY25–28E; Q4 FY26 OPM hit record 9.11%
~27–28%
Critical swing factor. Contracted to 27% (from 29% two years ago); recovery needed for bull case
~₹2.40
Expected 13% decline YoY despite revenue growth—valuation concern if miss occurs
A strong quarter would show gross margin recovery to 28%+, CVJ driveline volume momentum accelerating, and management confirming 8–10% FY27 revenue guidance. A weak quarter would be flat or declining gross margins, softer auto volumes, or CVJ ramp delays.
On Track?
JTEKT India outperformed the auto market in FY26 (11% revenue growth vs. 9% market growth), and gross margin erosion appears input-cost driven rather than competitive. The company's conservative leverage (debt-to-equity 0.09x) and new capacity initiatives (₹6.5 billion Gujarat facility, export scaling from ~3% to 8% of sales) support long-term growth. However, the near-term EPS headwind creates a timing risk: if earnings decline while multiples stay at 47.7x, near-term returns are capped. Management guidance on margin recovery, CVJ scale, and FY27 full-year outlook will be critical.
What the Street Says
Since Last Quarter
Aug 7, 2026
ApprovedRecord date for 75% final dividend (₹0.75/share)
Aug 4, 2026
PendingTax & Penalty: MEIS duty recovery demand ₹622.39 Cr (Show Cause Notice)
Jun 16, 2026
PendingTax demand ₹26.9 Lakh (Haryana entry tax notices)
May 7, 2026
PendingIncome tax demand ₹137.36 Mn for FY 2022–23
Jul 31, 2026
UpcomingAGM scheduled August 26, 2026; FY26 BRSR report submitted
The dividend at ₹0.75 (75% payout) signals confidence in cash generation—at ₹141 stock price, this yields ~5.3%, attractive for income investors. However, tax headwinds are material: a ₹622.39 Cr MEIS duty recovery demand is roughly 20% of trailing quarterly revenue run-rate and remains in Show Cause stage. Income tax demands (₹137.36 Mn for FY23) and state entry tax notices are worth monitoring for escalation, though typical regulatory friction at this scale.
1 · Gross Margin Trajectory
The centerpiece of the bull case. Expect management commentary on input-cost recovery, labour cost trends, and visibility into 28%+ margin recovery. Flat or declining gross margin would undermine the bull thesis and trigger multiple compression.
2 · CVJ Driveline Volume & Revenue Contribution
Currently 4% of sales; projected 45% CAGR through FY28E. Q1 data on order book, customer validation, and revenue ramp are critical to validate long-term upside. Weakness here signals limited optionality.
3 · FY27 Revenue & EBITDA Margin Guidance
Street expects 8–10% revenue growth and 9–10% EBITDA margins for full year. Confirmation defends current valuation; downside guidance could trigger sharp repricing given 47.7x P/E stretch.
4 · EPS Guidance vs. 13% Decline Consensus
Analyst models show FY27E EPS declining 13% despite revenue growth—a function of margin investments and capex drag. Management commentary on EPS trajectory and ROI payback on ₹6.5 Bn Gujarat capex is essential to justify current multiples.
5 · Tax Resolution Updates
Any progress on the ₹622.39 Cr MEIS duty demand (Show Cause stage) or income tax settlement would relieve near-term overhang. No resolution likely on August 13, but settlement progress would be positive.
JTEKT India's recent upgrade to Buy and ₹192 target reflect confidence in margin recovery and CVJ driveline scaling. However, the stock is priced at 47.7x trailing earnings and 24.9x PEG—multiples that leave little room for disappointment. Q1 results must confirm three things: (1) gross margin recovery is underway, (2) CVJ volumes are ramping on track, and (3) FY27 guidance supports 8–10% growth and 9–10% margins. Any shortfall on margins or guidance could trigger sharp repricing. The 5.3% dividend yield offers a floor in downside scenarios, but near-term upside hinges entirely on operational execution.